Dry-eye treatment shows promising Phase II results

Article

SARcode's lead investigational molecule, SAR 1118, demonstrated promising results in a Phase II study of dry eye disease, according to data presented at this year's Association for Research in Vision and Ophthalmology (ARVO) meeting

SARcode's lead investigational molecule, SAR 1118, demonstrated promising results in a Phase II study of dry eye disease, according to data presented at this year's Association for Research in Vision and Ophthalmology (ARVO) meeting.

The small molecule integrin antagonist inhibits T-cell medicated inflammation and can also be used to treat diabetic macular oedema.

Dr Charles Semba et al., SARcode Corporation, Brisbane, California, USA, conducted a randomized, placebo-controlled, multi centre study on 230 patients with dry eye disease. The Ocular Surface Disease Index (OSDI) was used to evaluate visual-related function. SAR 1118, the potent novel small molecule lymphocyte function-associated antigen, was topically administered to all patients.

It was concluded that SAR 1118 was safe and well tolerated amongst dry eye patients. There were no serious ocular effects recorded, most of them being transient and not related to the administration of SAR 1118. Corneal staining was reduced over 12 weeks, tear production increased after 2 weeks and visual-related functions vastly improved.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.